Yuyu Pharmaceutical has presented the results of a study for YDE, its peptide-based dry eye treatment, at the Association for Research in Vision and Ophthalmology (ARVO) held in Vancouver, Canada.
|Yuyu Pharmaceutical CEO Yu Won-sang (third from right) explains research results for its dry eye treatment, in Vancouver, Canada, on Sunday.|
The ARVO Secretariat selected Yuyu as a presenter after the company submitted an abstract on the results of the study to the secretariat. The research compared the therapeutic effects of YDE with existing therapeutic agents such as cyclosporine A, diquafosol, hyaluronic acid, and lipectagrast, by using a dry eye-induced mouse model.
Yuyu confirmed that compared with existing drugs, YDE showed the superior healing effect of corneal epithelial cell and improved tear secretion thanks to its excellent anti-inflammation mechanism.
“The results of the YDE study is different from the phase 2 clinical trial into YY-101, which was approved by the Ministry of Food and Drug Safety in March,” said Baik Tae-gon, head of Yuyu’s research center. “Based on the results of this study, the company plans to publish the results in international journals and prepare for global clinical trials.”
<© Korea Biomedical Review, All rights reserved.>